Ocrelizumab efficacy in subgroups of patients with relapsing multiple sclerosis

The efficacy and safety of ocrelizumab, versus interferon (IFN) β-1a, for the treatment of relapsing multiple sclerosis (RMS) from the identically designed OPERA I (NCT01247324) and OPERA II (NCT01412333) phase III studies has been reported; here we present subgroup analyses of efficacy endpoints from the pooled OPERA I and OPERA II populations.Patients with RMS were randomized to either ocrelizumab 600 mg administered by intravenous infusion...